Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)
Susanna J Lake, Sophie L Phelan, Daniel Engelman, Oliver Sokana, Titus Nasi, Dickson Boara, Christina Gorae, Tibor Schuster, Anneke C Grobler, Millicent H Osti, Ross Andrews, Michael Marks, Margot J Whitfeld, Lucia Romani, John Kaldor, Andrew Steer
BMJ Open | BMJ PUBLISHING GROUP | Published : 2020
INTRODUCTION: Scabies is a significant contributor to global morbidity, affecting approximately 200 million people at any time. Scabies is endemic in many resource-limited tropical settings. Bacterial skin infection (impetigo) frequently complicates scabies infestation in these settings. Community-wide ivermectin-based mass drug administration (MDA) is an effective control strategy for scabies in island settings, with a single round of MDA reducing population prevalence by around 90%. However, current two-dose regimens present a number of barriers to programmatic MDA implementation. We designed the Regimens of Ivermectin for Scabies Elimination (RISE) trial to investigate whether one-dose MD..View full abstract
Awarded by National Health and Medical Research Council of Australia (NHMRC)
This research is funded by the National Health and Medical Research Council of Australia (NHMRC) (APP1127297). DE, LR, JK and ACS are supported by fellowships from the NHMRC. MM is supported by the UK National Insitute for Health Research.